Platform
The microbiome:
Essential for health.
Harnessed for medicine.
The microbiome consists of trillions of microbes that live symbiotically in and on every human and are essential to our health. When key microbes are lost, the resulting dysbiosis (microbiome disruption) can increase susceptibility to immune disorders, infections, neurological conditions, cancer, and other serious conditions. We are leveraging our Human-First Discovery® platform to develop novel therapeutics designed to deliver missing microbes and their clinically relevant biochemical functions to correct dysbiosis and the conditions that emerge from it.
Our Human-First Discovery platform & product strategies
Our platform is fueled by data from human microbiota transplantation studies. These studies involve the transfer of microbiota from healthy individuals to individuals with disease, an area of intense research with hundreds of studies spanning dozens of different conditions. We leverage data from these types of studies, plus machine learning and molecular characterization techniques, to identify conditions where a disrupted microbiome is driving disease and to uncover the key dynamics associated with successful clinical outcomes.
Our platform enables the development of product candidates that deliver complete microbiome communities to restore broad community function and candidates that contain select microbes targeting specific biological pathways. This combination of capabilities positions us to develop three different types of candidates designed to address different types of dysbiosis that lead to microbiome-mediated conditions.
Complete Consortia
Delivers complete microbial community to restore broad community function
Enriched Consortia
Hybrid approach to restore broad community function and target specific pathways
Targeted Consortia
Delivers selected microbes to target specific biological pathways
Platform highlights:
Differentiated discovery process, with proof-of-concept clinical data leveraged to guide product design and de-risk development
Uniquely positioned to harness full diversity and potential of the microbiome across diverse therapeutic areas
Leading machine learning-based platform recognized by Takeda partnership
An industry leading IP portfolio
Finch’s platform and pipeline is protected by a leading patent portfolio with significant longevity and broad relevance for the industry.
Extensive, multi-layered
patent protection
- >55 issued U.S. and foreign patents and >140 patent applications pending
- Robust protection for lead candidate through 2036
Foundational patents
in the field
- Priority dates of foundational patent family predate the industry, enabling broad protection for composition of matter, methods of use, manufacture, and formulation claims through 2031
Broad & diverse
patent protection
- Protection for multiple microbiome product strategies, including donor-derived and donor-independent product strategies
- Diverse therapeutic coverage, with protection for a wide range of indications of interest
Finch publications
Other supporting literature
Fecal Microbiota Transplantation Relieves Gastrointestinal and Autism Symptoms by Improving the Gut Microbiota in an Open-Label Study Frontiers in Cellular and Infection Microbiology
Long-Term Benefit of Microbiota Transfer Therapy on Autism Symptoms and Gut Microbiota Scientific Reports
Combined Oral Fecal Capsules Plus Fecal Enema as Treatment of Late-Onset Autism Spectrum Disorder in Children: Report of a Small Case Series Open Forum Infectious Diseases
Fecal Microbiota Transplantation for Children with Autism Spectrum DisorderGastrointestinal Endoscopy
Dissecting the Contribution of Host Genetics and the Microbiome in Complex Behaviors Cell
IL-17a Promotes Sociability in Mouse Models of Neurodevelopmental Disorders Nature
Single Delivery of High-Diversity Fecal Microbiota Preparation by Colonoscopy Is Safe and Effective in Increasing Microbial Diversity in Active Ulcerative Colitis Inflammatory Bowel Diseases
Fecal Microbiota Transplantation Induces Remission in Patients with Active Ulcerative Colitis in a Randomized Controlled Trial Gastroenterology
Systematic Review and Meta-analysis: Fecal Microbiota Transplantation for Treatment of Active Ulcerative Colitis Inflammatory Bowel Diseases
Faecal Microbiota Transplantation for Inflammatory Bowel Disease: A Systematic Review and Meta-analysis Journal of Crohn’s and Colitis
Fecal Microbiota Transplant Overcomes Resistance to Anti–PD-1 Therapy in Melanoma Patients Science
Fecal Microbiota Transplant Promotes Response in Immunotherapy-Refractory Melanoma Patients Science
Gut Microbiome Influences Efficacy of PD-1-Based Immunotherapy Against Epithelial Tumors Science
Fecal Microbiota Transplantation in Hepatitis B e Antigen-Positive Chronic Hepatitis B Patients: A Pilot Study Digestive Diseases and Sciences
Age-Related Immune Clearance of Hepatitis B Virus Infection Requires the Establishment of Gut Microbiota Proceedings of the National Academy of Sciences of the United States of America